Evaluating BA3182 for advanced adenocarcinoma treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1 study aims to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of BA3182 in patients diagnosed with advanced adenocarcinoma. It is a multi-center, open-label trial that includes patients with locally advanced unresectable or metastatic forms of the disease. Participants will receive BA3182 and will be monitored for various health parameters to determine the treatment's efficacy and safety profile.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically or cytologically confirmed locally advanced unresectable or metastatic adenocarcinoma
* Age ≥ 18 years
* Adequate renal function
* Adequate liver function
* Adequate hematological function
* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Exclusion Criteria:

* Patients must not have clinically significant cardiac disease.
* Patients must not have known non-controlled CNS metastasis.
* Patients must not have active autoimmune disease or a documented history of autoimmune disease.
* Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as wellas known or suspected allergy or intolerance to any agent given during this study.
* Patients must not incomplete recovery from the effects of major surgery or significant traumatic injury before the first dose of study treatment.
* Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C.
* Patients must not be women who are pregnant or breast feeding.

Where it's running

• UC Irvine
  Irvine, California, United States Recruiting
• USC Norris Comprehensive Cancer Center
  Los Angeles, California, United States Recruiting
• Yale Cancer Center
  New Haven, Connecticut, United States Recruiting
• Northwestern University
  Chicago, Illinois, United States Recruiting
• University of Illinois
  Chicago, Illinois, United States Recruiting
• Karmanos Cancer Institute
  Detroit, Michigan, United States Recruiting

Study contacts

• Study coordinator: BioAtla Medical Affairs
• Email: medicalaffairs@bioatla.com
• Phone: 858-558-0708

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating a blood test for detecting colorectal cancer and precancerous lesions

  This study is testing a blood test to see if it can help find colorectal cancer and serious precancerous growths in people aged 45 and older who are at average risk.

  Recruiting Universal Diagnostics · Raonoke, Virginia · NCT06059963

• AB801 with chemotherapy and immunotherapy for cholangiocarcinoma and pancreatic cancer

  This phase 1 study tests whether AB801 can be given safely with chemotherapy and immunotherapy in adults with border-line resectable, locally advanced, or metastatic cholangiocarcinoma or pancreatic cancer.

  Recruiting Phase 1 Jonsson Comprehensive Cancer Center · Los Angeles, California · NCT07619313

• Surgery after tumor-shrinking treatment for locally advanced pancreatic cancer

  This project will test whether doing surgery after at least four months of chemotherapy helps people with locally advanced pancreatic cancer that was initially considered not removable live longer and feel better.

  Recruiting Azienda Ospedaliera di Padova · Padova · NCT07241663

• XER-001 (nasoduodenal amifostine) with SBRT for locally advanced pancreatic cancer

  This trial tests whether giving XER-001 through a nasoduodenal tube together with stereotactic body radiotherapy (SBRT) is safe and helpful for people with locally advanced pancreatic cancer.

  Recruiting at 5 sites Phase 1/2 Xerient Pharma · Duarte, California and 4 other locations · NCT07157033

• Comparing NALIRIFOX to a modified gemcitabine/nab‑paclitaxel/cisplatin regimen for advanced pancreatic adenocarcinoma

  This compares NALIRIFOX to a modified gemcitabine/nab‑paclitaxel/cisplatin regimen to see if it helps people with untreated locally advanced or metastatic pancreatic ductal adenocarcinoma live longer or have better tumor responses.

  Recruiting at 2 sites Phase 2 Medical University of South Carolina · Charleston, South Carolina and 1 other locations · NCT07076212

• Adding panitumumab to chemotherapy for unresectable or metastatic KRAS wild-type pancreatic cancer

  This trial will test whether giving the antibody panitumumab along with standard chemotherapy helps people with unresectable, locally advanced, or metastatic KRAS wild-type pancreatic cancer live longer.

  Recruiting at 272 sites Phase 3 SWOG Cancer Research Network · Anchorage, Alaska and 273 other locations · NCT06998940

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.